Thursday, November 10, 2005

Oncotype DX™ Test May Predict Outcome for Some Breast Cancer Patients

I am posting this because this test actually prevented Mia from undergoing unnecessary chemotherapy and I think everyone should know about it. It was recommended and administered by our hematology oncologist at the Cleveland Clinic. You'll see a description below as well as an additional link to the official website, run by the test's creators Genomic Health.

If you or someone you love qualifies for the test -- Stage I or II breast cancer, estrogen receptor positive (ER+), and node-negative (your lymph nodes do not contain cancer cells) -- please, please, please work with your doctor and insurance company to arrange to be screened!

"Oncotype DX™ is a diagnostic test that quantifies the likelihood of disease recurrence in women with early stage breast cancer and assesses the likely benefit from certain types of chemotherapy. With this information, it may be possible for doctors and patients to make more informed decisions about breast cancer treatment options. Oncotype DX analyzes a specific set of genes within a tumor to determine a Recurrence Score™.The Recurrence Score is a number between 0 and 100 that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis."


Post a Comment

<< Home

/* WebRing Code */